Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Probucol Combined with Moderate-Dose Statins in High-Risk ASCVD Patients
ChiCTR2600122193Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of probucol in atherosclerotic disease and hypercholesterolemia, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Low-density lipoprotein cholesterol (LDL-C) at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
probucol
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on ChiCTR2600122193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122193.